Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)

NCT01406327 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01406327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01406327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
December 14, 2010
Completion date
February 28, 2020
Enrollment
900 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary